Fineline Cube

Follow:
14691 Articles
Novartis Exercises Exclusive Option to Acquire Global Rights to Sironax Brain Delivery Platform – USD 125 Million Transaction Targets Blood‑Brain Barrier Breakthrough for CNS Diseases
CompanyDeals

Novartis Exercises Exclusive Option to Acquire Sironax Brain Delivery Platform in USD 125 Million Transaction

China Resources Pharmaceutical and Sino Biopharmaceutical Sign Strategic Pact Spanning R&D, Distribution and DTP Channels Toward RMB 10 Billion Target
CompanyDeals

China Resources Pharmaceutical and Sino Biopharmaceutical Sign Strategic Pact Spanning R&D, Distribution and DTP Channels Toward RMB 10 Billion Target

Tempest Therapeutics Secures Exclusive Option to License Senlang's CD7‑Targeted In Vivo CAR‑T Platform – Lead Bispecific BCMA/GPRC5D Candidate in Phase I for Relapsed/Refractory Multiple Myeloma
CompanyDeals

Tempest Therapeutics Secures Exclusive Option to License Senlang’s CD7‑Targeted In Vivo CAR‑T Platform – Lead Bispecific BCMA/GPRC5D Candidate in Phase I for Relapsed/Refractory Multiple Myeloma

ACROBiosystems and MediumBank Forge Strategic Partnership on AI‑Designed Proteins – Closed‑Loop Program Targets Thermostable bFGF and High‑Activity Cytokines for Cell Culture Media
CompanyDeals

ACROBiosystems and MediumBank Forge Strategic Partnership on AI‑Designed Proteins – Closed‑Loop Program Targets Thermostable bFGF and High‑Activity Cytokines for Cell Culture Media

NMPA Accepts Qilu Pharmaceutical's Marketing Application for Meropenem/Pralurbactam for Injection – First Independently Developed Novel β‑Lactamase Inhibitor Combination in China for cIAI
CompanyDrug

NMPA Accepts Qilu Pharmaceutical’s Marketing Application for Meropenem/Pralurbactam for Injection – First Independently Developed Novel β‑Lactamase Inhibitor Combination in China for cIAI

Escugen and Sovran Bio Sign Co‑Development Agreement for First‑in‑Class Pan‑Tumor Bispecific ADC – EZWi‑Fit Platform Powers Tumor‑Selective Payload Delivery
CompanyDeals

Escugen and Sovran Bio Sign Co‑Development Agreement for First‑in‑Class Pan‑Tumor Bispecific ADC – EZWi‑Fit Platform Powers Tumor‑Selective Payload Delivery

Hengrui's HRS-4139 Wins NMPA Clinical Trial Approval – Class 1 First‑in‑Target Candidate Targets Moderate‑to‑Severe Plaque Psoriasis
CompanyDrug

Hengrui’s HRS-4139 Wins NMPA Clinical Trial Approval – Class 1 First‑in‑Target Candidate Targets Moderate‑to‑Severe Plaque Psoriasis

IASO Bio's In Vivo CAR‑T IASO208 Receives FDA Implicit IND Approval – Off‑the‑Shelf CD20 Therapy Targets Relapsed/Refractory B‑NHL
CompanyDrug

IASO Bio’s In Vivo CAR‑T IASO208 Receives FDA Implicit IND Approval – Off‑the‑Shelf CD20 Therapy Targets Relapsed/Refractory B‑NHL

Chia Tai Tianqing's Dual Category 1 Biologics Applications Accepted by NMPA – TQB2102 HER2‑Low ADC and TQH2722 IL‑4Rα Antibody Advance Toward Approval
CompanyDrug

Chia Tai Tianqing’s Dual Category 1 Biologics Applications Accepted by NMPA – TQB2102 HER2‑Low ADC and TQH2722 IL‑4Rα Antibody Advance Toward Approval

CSPC's SYS6010 Granted NMPA Breakthrough Therapy Designation – EGFR‑Targeting ADC for Refractory Non‑Squamous NSCLC
CompanyDrug

CSPC’s SYS6010 Granted NMPA Breakthrough Therapy Designation – EGFR‑Targeting ADC for Refractory Non‑Squamous NSCLC

Gilead and PAHO Sign Agreement to Expand Twice-Yearly Lenacapavir PrEP Access Across Latin America and the Caribbean
CompanyDeals

Gilead and PAHO Sign Agreement to Expand Twice-Yearly Lenacapavir PrEP Access Across Latin America and the Caribbean

China's NHSA Pilots Pre-Project Approval System for Medical Service Pricing – Fast Lane for Innovative Technologies
Policy / Regulatory

China’s NHSA Pilots Pre-Project Approval System for Medical Service Pricing – Fast Lane for Innovative Technologies